| July 1 |
Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta (Formerly Lymphostat-B in Systemic Lupus Erythematosus |
| July 1 |
Pharming Confirms Positive Results From Fina l Analysis Of Rhucin Studies |
| July 1 |
New Review on Prostvac Published by Key Investigators From NCI |
| July 1 |
Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa |
| July 1 |
Study Showed Vyvanse (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment |
| July 1 |
Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory Diseases |
| July 2 |
Sucampo Reports Top-Line Results of Phase 2 Clinical Trial of Cobiprostone for Prevention of NSAID-Induced Gastrointestinal Injuries |
| July 2 |
Lu AA24530 shows positive results in major depressive disorder phase II study |
| July 2 |
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA Pediatrics |
| July 2 |
iCo Therapeutics Publishes Review of Diabetic Retinopathy Treatment |
| July 2 |
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion |
| July 6 |
5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus Compared to NPH |
| July 6 |
Aeolus Pharmaceuticals' AEOL 10150 Significantly Increases Survival in Mice Exposed to Radiation when Administered After Exposure |
| July 6 |
New Online Resource Launches For Patients With Chronic Myeloid Leukemia |
| July 7 |
XOMA Announces Conference Call and Webcast On July 14 to Review Top Line Multi-dose and Other Results of Its Phase 1 Clinical Trial of XOMA 052 in Type 2 Diabetes |
| July 7 |
Vical Announces News Release and Conference Call/Webcast Schedule to Present TransVax CMV Vaccine Phase 2 Interim Efficacy Results |
| July 7 |
Published in The Lancet...Cervarix protects against the five most common cancer-causing virus types |
| July 7 |
Presse Release: Further interim analyses confirm good clinical efficacy of the BT-061 monoclonal antibody. |
| July 7 |
South Jersey Healthcare Selects MobileMD for Health Information Exchange Service |
| July 7 |
Stinson Brand Innovation, Inc. Releases White Paper Trends In Pharma Branding Over The Next Five Years |
| July 7 |
Denosumab Demonstrates Superiority Over Zometa in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases |
| July 7 |
EnVivo to Share Results of its EVP-6124 Phase Ib/IIa Trial at The International Conference on Alzheimer's Disease |
| July 7 |
Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet |
| July 7 |
AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction |
| July 8 |
ARYx Therapeutics Announces Results of Phase 2/3 Clinical Trial on Anticoagulant Agent Tecarfarin |
| July 8 |
Livingston Securities ?Healthcare Investment Series? Webinar Covers Emerging Models for Pharma Exits and Deals |
| July 8 |
Beacon Solutions Announces New Purchase Order from Fortune 500 Pharmaceutical Company |
| July 8 |
BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis |
| July 8 |
McKesson Provider Technologies Deploys Synygy Sales Performance Management Solution |
| July 8 |
Digital Consumer Solutions Inc Launches DCSI Content Network |
| July 8 |
Vical TransVax CMV Vaccine Achieves Promising Interim Clinical Results in Phase 2 Trial |
| July 9 |
Revance Therapeutics Announces Efficacy of Topical Botulinum Toxin Type A for the Treatment of Facial Wrinkles |
| July 9 |
Elan to Showcase Its Leadership in Alzheimer's Disease at Upcoming International Meeting |
| July 9 |
Array BioPharma Announces Top-Line Results in Two Phase 1 Clinical Trials |
| July 9 |
Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial |
| July 9 |
Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax) for the Treatment of Inhalation Anthrax |
| July 9 |
Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity |
| July 9 |
Questcor Launches New Corporate Website |
| July 9 |
Physicians and Pharmacists Reach for OTC Relief With New Epocrates Reference |
| July 9 |
Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine and Epinephrine is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in a Phase 2 Clinical Trial |
| July 13 |
Elan and Transition Therapeutics Announce Phase 1 Data Showing ELND005 Achieves Desired Concentrations in Brain Tissue and Cerebrospinal Fluid |
| July 13 |
New Data from Phase III SATURN Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer |
| July 13 |
CytRx's INNO-206 Demonstrates Statistically Significant Tumor Shrinkage in Animal Trial for Breast Cancer |
| July 14 |
Maxygen Announces Positive Results of MAXY-G34 Phase IIa Study in Breast Cancer Patients |
| July 14 |
Noven Reports Positive Phase 2 Results for Mesafem Non-Hormonal Therapy for Vasomotor Symptoms |
| July 14 |
IP Advocate Enhances Interactive IPAO Forum with New ?Expert Opinions' Section |
| July 14 |
Safety and Cognitive Stability Are Key Findings in Phase IIA Trial of New Alzheimer's Disease Treatment from Humanetics Corporation |
| July 14 |
Light-directed drug delivery system slows growth of invasive tumours |
| July 14 |
Oxford Biomedica Announces Update On Phase I/Ii Study Of Prosavin In Parkinson's Disease |
| July 14 |
Avid Radiopharmaceuticals Phase II Results Featured in Two Presentations at Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD) |
| July 14 |
New Podcast in Patient Perspectives Series: Searching for a Cure |
| July 14 |
EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimer's Disease Transgenic Mouse Model With Gamma-Secretase Modulator |
| July 14 |
Study Evaluating Efficacy and Safety of Two Low-dose Regimens of Premarin Vaginal Cream for the Treatment of Moderate to Severe Vaginal Atrophy Now Published |
| July 14 |
Endocyte to Present Data on EC145 at the IASLC 13th World Conference on Lung Cancer |
| July 14 |
ParagonRx Creates New Website Featuring REMS Help Center for Pharma |
| July 14 |
Patient Enrollment Complete for Phase I/II Clinical Trial for GALNS for Morquio A Syndrome |
| July 14 |
Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII |
| July 15 |
I-many Government Pricing Goes Live at Graceway Pharmaceuticals |
| July 15 |
Abraxis BioScience Completes Enrollment of Pivotal Phase III Advanced Lung Cancer Study Evaluating ABRAXANE Vs. Taxol |
| July 15 |
Targacept's TC-5214 Achieves All Primary and Secondary Outcome Measures in Phase 2b Trial as Augmentation Treatment for Major Depressive Disorder |
| July 15 |
Oncolytics Biotech Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting |
| July 15 |
Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing |
| July 15 |
A Phase III Alzheimer's Drug Increases Levels of Beta Amyloid in the Brain - But Still Provides Benefits |
| July 15 |
Results From Drug Trials and New Risk Factors Announced at International Alzheimer's Conference |
| July 15 |
Pfizer Announces New Phase 1 Data From Two Novel Compounds For Alzheimer's Disease At ICAD Annual Meeting |
| July 15 |
Sapient Delivers New Online Multilingual Resource to Support Thousands of Families Affected by Rare Congenital Syndrome |
| July 15 |
ReachMD Announces a New Radio Programming Series, ?Diabetes Discourse,? hosted by Steven V. Edelman, MD |
| July 16 |
National Survey Indicates Latinos and Blacks in America Twice as Likely as Caucasians to Be Diagnosed with Diabetes |
| July 16 |
Results of Phase I and Phase IIa Clinical Studies Confirm the Inhibitory Effect of Proprietary Ipsen's BIM23A760 First-in-Class ?Chimeric? Compound on Growth Hormone, IGF-1 and Prolactin Levels1 |
| July 16 |
Inovio Biomedical H1N1 Influenza DNA Vaccines Demonstrate 100% Responses Against Swine Flu in Vaccinated Pigs |
| July 16 |
avVaa World Health Care Products Inc. Announces Web Site Design for Neuroskin Psoriasis Relief DRTV Campaign |
| July 16 |
Results of Phase I and Phase IIa clinical studies confirm the inhibitory effect of proprietary Ipsen?s BIM23A760 first-in-class ?chimeric? compound on growth hormone, IGF-1 and prolactin levels |
| July 16 |
Penwest Announces Results of Phase Ib Trial of A0001 |
| July 16 |
Targacept?s TC-5214 Achieves All Primary and Secondary Outcome Measures in Phase 2b Trial as Augmentation Treatment for Major Depressive Disorder |
| July 16 |
Raptor Pharmaceuticals Corp. to Present at 2009 Cystinosis Research Network Family Conference |
| July 16 |
XOMA Announces Positive Results From U.S. Phase 1 Trial of XOMA 052 in Type 2 Diabetes |
| July 16 |
Oncolytics Biotech Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC |
| July 16 |
Former AMA Chief and Other Members of the Coalition to Protect Patients' Rights to Hold Press Conference to Discuss Health Reform |
| July 17 |
Bionovo's Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity |
| July 17 |
BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza |
| July 17 |
PolyMedix to Present at 5th International AIDS Society (IAS) Conference |
| July 19 |
Data on PolyMedix Heptagonist Compounds Presented at the International Society on Thrombosis and Hemostasis (ISTH) Conference |
| July 20 |
Alnylam and Cubist Announce Complete Data from Phase II Study of ALN-RSV01 in Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus |
| July 20 |
First Potential Lupus-Specific Treatment in Sight |
| July 20 |
Debate Over Advertising Prescription Drugs to Consumers Goes Online at New ProCon.org Website |
| July 21 |
Xeloda-Oxaliplatin Combination (XELOX) Shown to Be More Effective Than Standard Chemotherapy Regimen in Adjuvant Colon Cancer |
| July 21 |
Isentress (raltegravir), from Merck, was as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-Naïve Patients up to 144 Weeks When Used in Combination Therapy |
| July 21 |
Exenatide Once Weekly Provided Superior Glucose Control Compared To Lantus in Head-to-Head DURATION-3 Study |
| July 21 |
96-Week MERIT ES Analysis Shows Efficacy Of Pfizer's HIV/AIDS Treatment Celsentri/Selzentry (Maraviroc) In Treatment-Naïve HIV Patients; Results Consistent With 48-Week Analysis |
| July 21 |
Foresight Biotherapeutics Announces Positive Results from an Open Label Pilot Study in Patients with Viral Conjunctivitis |
| July 21 |
Thermo Fisher Scientific Showcases Breadth of Clinical Chemistry Solutions at AACC 2009 |
| July 21 |
Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients |
| July 21 |
Isentress (raltegravir), from MSD, was as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-Naïve Patients up to 144 Weeks When Used in Combination Therapy |
| July 21 |
Raltegravir as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-Naive Patients Up to 144 Weeks When Used in Combination Therapy |
| July 21 |
Orexigen Successfully Meets Phase 3 Endpoints in Obesity Trials |
| July 22 |
Takeda and Sucampo Report Top-Line Results of Two Phase 3 Trials of Lubiprostone in Opioid-Induced Bowel Dysfunction |
| July 22 |
-Contrave Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- |
| July 22 |
Actelion's PGI2 receptor agonist demonstrates efficacy in pulmonary arterial hypertension patients - Morbidity-Mortality Phase III study to be initiated before year-end |
| July 22 |
The American Academy of Pharmaceutical Scientists (AAPS) Hires Environics Communications to Provide PR for Annual Meeting |
| July 22 |
96-Week Safety and Efficacy Findings Presented for Intelence (etravirine) As Part of HIV Combination Therapy |
| July 22 |
AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine |
| July 22 |
BIO Issues Call for Sessions for 2010 BIO International Convention |
| July 22 |
Data Show ATryn Effectively Prevents Serious Blood Clots in Patients with Hereditary Antithrombin Deficiency |
| July 22 |
FoldRx Pharmaceuticals Announces Positive Results from Pivotal Phase II/III Clinical Study of Tafamidis |
| July 22 |
Siemens Showcases Innovative Products and Educational Offerings |
| July 22 |
Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference |
| July 22 |
Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration |
| July 22 |
NCCN Will Convene National Policy Summit on Comparative Effectiveness in Cancer Care |
| July 22 |
Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer |
| July 22 |
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2009 Financial Results on July 23, 2009 |
| July 22 |
PolyMedix to Present at 5th International AIDS Society (IAS) Conference Cape Town, South Africa |
| July 22 |
New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed |
| July 22 |
SoCalBio's 11th Investor & Partnership Conference to Explore Post-Recession Funding Strategies for Life Science Firms |
| July 22 |
New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies |
| July 22 |
Merck Issues Statement on WHO Study Showing First Evidence That Elimination of River Blindness is Feasible in Africa |
| July 23 |
Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis |
| July 23 |
Landmark Five-Year African Study Indicates That HIV Therapy May Be Given Safely in Resource-Limited Settings Without Routine Laboratory Monitoring |
| July 23 |
Millennium Laboratories Research Study Reveals Lower Opiate Cutoff Levels Identify Higher Percentage of Patients Taking Illegal Drugs |
| July 23 |
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for Benlysta in Systemic Lupus Erythematosus |
| July 24 |
Orexo announces positive Phase III results for KW-2246 in Japan |
| July 24 |
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent |
| July 24 |
Advancing Adaptive Design and Personalized Medicine in CNS Trials: Clinical, Regulatory and Statistical Viewpoints |
| July 24 |
Chinese Scientist Fanyi Zeng to Present at World Stem Cell Summit on iPS Cells Producing Viable Mice |
| July 24 |
ChemOutsourcing Unveils 2009 Attendee List for September Show in New Jersey |
| July 27 |
ARIAD Announces Preliminary Results from Ongoing Clinical Trial of Its Investigational, Bcr-Abl Inhibitor ? AP24534 ? in Drug-Resistant Chronic Myeloid Leukemia |
| July 27 |
Inovio Biomedical Universal Dengue DNA Vaccine Demonstrates Strong Immune Responses Against All Four Serotypes |
| July 28 |
Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms |
| July 28 |
Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression |
| July 28 |
Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma |
| July 28 |
Saphris (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia |
| July 28 |
Suven Presented Positive Phase-I clinical data of SUVN-502 for Alzheimer's disease at ICAD 2009, Vienna, Austria |
| July 28 |
NeurogesX Announces Preliminary Results of FDA-Requested Qutenza Study |
| July 28 |
Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis |
| July 28 |
CytRx Drug Candidate INNO-206 Results in Ovarian Tumor Shrinkage in Animal Trials |
| July 28 |
Economy is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease |
| July 28 |
Ongoing Study Shows That Endovascular Therapy is Associated With High Cure Rate for Childhood Eye Cancer |
| July 28 |
Biofrontera AG (DE) - Ad hoc: Clinical study with BF-derm1 shows efficacy in severe chronic urticaria |
| July 28 |
Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy |
| July 29 |
DURECT to Present at the BMO Capital Markets Healthcare Conference |
| July 29 |
ImmuneRegen BioSciences Confirms Homspera's Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration |
| July 29 |
QuatRx Announces Further Positive Phase 3 Results For Ophena (Ospemifene Tablets) in Postmenopausal Vaginal Atrophy |
| July 29 |
NanoBio to Announce Key Preclinical Data on Nanoemulsions for the Treatment of Acne at American Academy of Dermatology Summer Meeting |
| July 29 |
Sciele Pharma and Plethora Solutions Announce Positive Results of Final Phase III Pivotal Trial for PSD502 for Premature Ejaculation |
| July 29 |
Foundation for the National Institutes of Health Announces 2009 mHealth Summit |
| July 29 |
Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis |
| July 30 |
Obagi Medical Products Releases Results of a Clinical Trial Showing Optimized Patient Outcomes When Condition & Enhance System is Used in Combination with Botulinum Toxin Type A |
| July 30 |
Obagi Medical Products Reveals Results of a Meta-Analysis Comparing the Company's Novel 5 Percent Solubilized BPO to Other Prescription 5 Percent BPO and Combination BPO/Clindamycin Topical Products |
| July 30 |
Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference |
| July 30 |
Child and Adolescent Psychiatry and Mental Health Publishes Vyvanse ADHD Data |
| July 30 |
Cardinal Health Welcomes Record Number of Attendees at its Annual Independent Pharmacy Trade Show |
| July 30 |
Teva's Forum Draws Key Pennsylvania Healthcare Leaders |
| July 30 |
Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose |
| July 31 |
Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C |
| July 31 |
Clinical Trial by Licensee Does Not Meet Primary Endpoint |
| July 31 |
Second Phase III Study Showed Lucentis Improved Vision in Patients With Retinal Vein Occlusion |
| July 31 |
AVEO's Tivozanib Demonstrates Anti-Tumor Activity in Engineered Lung Tumors Exhibiting Treatment Resistant Mutations |
| July 31 |
17 Regional Companies Accepted During First-Round Vetting for the Inaugural Rocky Mountain Life Science Investor Conference, September 17th in Denver |
| July 31 |
Obagi Medical Products' CLENZIderm M.D. Serum Gel Significantly Reduces Non-Inflammatory Lesions with Visible Results as Early as Week One |
